Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Interventional Cardiology
What are your key takeaways regarding the difference in findings for BETA-MI DANBLOCK and REBOOT in patients post-MI with LVEF >40%?
Related Questions
How do the results of CREST-2 influence your recommendations on screening for asymptomatic carotid stenosis?
What has been your approach to minimizing the risk of vascular complications when placing Impella support devices?
How do you manage anticoagulation/antiplatelet therapies with strong indications for uninterrupted therapy in setting of urgent procedures?
Should CYP2C19 genotype testing be performed in patients presenting with ISR on Plavix?
Do you prefer using echocardiographic guided or SmartAssist guided help for Impella repositioning, and why?
Would you favor culprit-only PCI, complete revascularization via percutaneous approach, or urgent CABG evaluation for a young diabetic patient with newly reduced LVEF < 35% presenting with an anterior STEMI and multivessel disease?
Would acute-onset thrombocytopenia and concern for active bleeding with platelet count below 50,000 prompt you to hold plavix and/or aspirin following PCI that was done 1-2 weeks ago?
For patients presenting with suspected type 1 NSTEMI and atrial fibrillation on anticoagulation, do you favor triple therapy or SAPT with systemic anticoagulation instead while awaiting LHC?
What would be your percutaneous approach to a severely stenotic bifurcation lesion with a large aneurysm post-stenosis?
Do you always give 325mg aspirin if not already loaded with antiplatelets prior to the start of every LHC, even just for diagnostics in the absence of ACS?
